

Special Issue

Advances in the Management of Thyroid Cancer

Message from the Guest Editor

The thyroid gland can harbor one of the most indolent of human cancers, micropapillary carcinoma, but also give rise to one of the most aggressive and lethal of human cancers, anaplastic carcinoma, with a rainbow of cancers of varying histologies and prognoses in between. Advances have been made in recent years on both sides of the spectrum, from “less is more” active surveillance for small papillary carcinomas to personalized molecular-based targeted therapies for metastatic disease and anaplastic carcinoma. With improved knowledge of molecular pathways, redifferentiation to induce radioactive iodine uptake in refractory tumors is also now a reality. New surgical and minimally invasive techniques are now applied both for primary surgery and for effectively treating oligometastatic disease. This Special Issue on “Advances in the Management of Thyroid Cancer” will cover recent progress in treatment of the lowest risk to the highest risk cancers and provide insight for future therapies and clinical trials.

Guest Editor

Dr. Dana Hartl

Département Anesthésie Chirurgie et Interventionnel, Gustave Roussy,
112 rue Edouard Vaillant, 94805 Villejuif, France

Deadline for manuscript submissions

closed (30 June 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/81695

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)